FDA Announces Public Meeting of Cellular, Tissue and Gene Therapies Advisory Committee to Discuss Gene Therapy Risks

Summary

The US Food and Drug Administration (FDA) is hosting a public meeting of its Cellular, Tissue and Gene Therapies Advisory Committee to discuss potential toxicity risks associated with adeno-associated virus (AAV) vector-based gene therapy products, and is seeking public comments on the matter